Evidence map›Paper›PMID 26240133›Full record

ArticleThe oncologist2015

The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia.

Hung-Yang Kuo, Zhong-Zhe Lin, Raymond Kuo, Wen-Yi Shau, Chiu-Lin Lai, Yen-Yun Yang, Yu-Yun Shao, Chiun Hsu, Wen-Fan Cheng, Ann-Lii Cheng and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Cervical carcinoma and diabetes mellitus among women in Southern India.Przeglad menopauzalny = Menopause review · 2024
    Article
  7. Associations between Diabetes Mellitus and Selected Cancers.International journal of molecular sciences · 2024
    Review
  8. Article
  9. Article
  10. Insulin Resistance: The Increased Risk of Cancers.Current oncology (Toronto, Ont.) · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Hung-Yang KuoDepartment of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan, Republic of China; Departments of Oncology, Internal Medicine, and Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; Graduate Institute of Oncology, College of Medicine, and Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China; Center for Comparative Effectiveness Research, National Center of Excellence for Clinical Trial and Research, Taipei, Taiwan, Republic of China; Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan, Republic of China; Taiwan Cancer Registry, Taipei, Taiwan, Republic of China.
Zhong-Zhe LinDepartment of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan, Republic of China; Departments of Oncology, Internal Medicine, and Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; Graduate Institute of Oncology, College of Medicine, and Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China; Center for Comparative Effectiveness Research, National Center of Excellence for Clinical Trial and Research, Taipei, Taiwan, Republic of China; Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan, Republic of China; Taiwan Cancer Registry, Taipei, Taiwan, Republic of China.
Raymond KuoDepartment of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan, Republic of China; Departments of Oncology, Internal Medicine, and Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; Graduate Institute of Oncology, College of Medicine, and Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China; Center for Comparative Effectiveness Research, National Center of Excellence for Clinical Trial and Research, Taipei, Taiwan, Republic of China; Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan, Republic of China; Taiwan Cancer Registry, Taipei, Taiwan, Republic of China.
Wen-Yi ShauDepartment of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan, Republic of China; Departments of Oncology, Internal Medicine, and Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; Graduate Institute of Oncology, College of Medicine, and Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China; Center for Comparative Effectiveness Research, National Center of Excellence for Clinical Trial and Research, Taipei, Taiwan, Republic of China; Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan, Republic of China; Taiwan Cancer Registry, Taipei, Taiwan, Republic of China.
Chiu-Lin LaiDepartment of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan, Republic of China; Departments of Oncology, Internal Medicine, and Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; Graduate Institute of Oncology, College of Medicine, and Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China; Center for Comparative Effectiveness Research, National Center of Excellence for Clinical Trial and Research, Taipei, Taiwan, Republic of China; Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan, Republic of China; Taiwan Cancer Registry, Taipei, Taiwan, Republic of China.
Yen-Yun YangDepartment of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan, Republic of China; Departments of Oncology, Internal Medicine, and Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; Graduate Institute of Oncology, College of Medicine, and Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China; Center for Comparative Effectiveness Research, National Center of Excellence for Clinical Trial and Research, Taipei, Taiwan, Republic of China; Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan, Republic of China; Taiwan Cancer Registry, Taipei, Taiwan, Republic of China.
Yu-Yun ShaoDepartment of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan, Republic of China; Departments of Oncology, Internal Medicine, and Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; Graduate Institute of Oncology, College of Medicine, and Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China; Center for Comparative Effectiveness Research, National Center of Excellence for Clinical Trial and Research, Taipei, Taiwan, Republic of China; Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan, Republic of China; Taiwan Cancer Registry, Taipei, Taiwan, Republic of China.
Chiun HsuDepartment of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan, Republic of China; Departments of Oncology, Internal Medicine, and Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; Graduate Institute of Oncology, College of Medicine, and Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China; Center for Comparative Effectiveness Research, National Center of Excellence for Clinical Trial and Research, Taipei, Taiwan, Republic of China; Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan, Republic of China; Taiwan Cancer Registry, Taipei, Taiwan, Republic of China.
Wen-Fan ChengDepartment of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan, Republic of China; Departments of Oncology, Internal Medicine, and Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; Graduate Institute of Oncology, College of Medicine, and Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China; Center for Comparative Effectiveness Research, National Center of Excellence for Clinical Trial and Research, Taipei, Taiwan, Republic of China; Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan, Republic of China; Taiwan Cancer Registry, Taipei, Taiwan, Republic of China.
Ann-Lii ChengDepartment of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan, Republic of China; Departments of Oncology, Internal Medicine, and Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; Graduate Institute of Oncology, College of Medicine, and Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China; Center for Comparative Effectiveness Research, National Center of Excellence for Clinical Trial and Research, Taipei, Taiwan, Republic of China; Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan, Republic of China; Taiwan Cancer Registry, Taipei, Taiwan, Republic of China.
James Chih-Hsin YangDepartment of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan, Republic of China; Departments of Oncology, Internal Medicine, and Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; Graduate Institute of Oncology, College of Medicine, and Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China; Center for Comparative Effectiveness Research, National Center of Excellence for Clinical Trial and Research, Taipei, Taiwan, Republic of China; Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan, Republic of China; Taiwan Cancer Registry, Taipei, Taiwan, Republic of China chihyang@ntu.edu.tw mslai@cph.ntu.edu.tw.
Mei-Shu LaiDepartment of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan, Republic of China; Departments of Oncology, Internal Medicine, and Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; Graduate Institute of Oncology, College of Medicine, and Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China; Center for Comparative Effectiveness Research, National Center of Excellence for Clinical Trial and Research, Taipei, Taiwan, Republic of China; Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan, Republic of China; Taiwan Cancer Registry, Taipei, Taiwan, Republic of China chihyang@ntu.edu.tw mslai@cph.ntu.edu.tw.
National Taiwan University · TWDevelopment Center for Biotechnology · TWCheng Hsin General Hospital · TWTaipei Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany studies have shown that type 2 diabetes mellitus (DM) increases the risk for several types of cancer but not cervical cancer (CC). Although DM and insulin-like growth factor 1 have preclinical and clinical implications for CC, less is known about the prognostic impact of DM on patients with early stage CC. PATIENTS AND

methodsWe used the nationwide Taiwan Cancer Registry database to collect the characteristics of stage I-IIA cervical cancer patients diagnosed between 2004 and 2008. DM and other comorbidities were retrieved from the National Health Insurance database. Cervical cancer-specific survival (CSS) and overall survival (OS) times of patients according to DM status were estimated using the Kaplan-Meier method. We used a Cox proportional hazards model to calculate adjusted hazard ratios (HRs) for the effects of DM and other risk factors on mortality.

resultsA total of 2,946 patients had primary stage I-IIA CC and received curative treatments, and 284 (9.6%) had DM. The 5-year CSS and OS rates for patients with DM were significantly lower than those without DM (CSS: 85.4% vs. 91.5%; OS: 73.9% vs. 87.9%). After adjusting for clinicopathologic variables and comorbidities, DM remained an independent unfavorable prognostic factor for CSS (adjusted HR: 1.46) and OS (adjusted HR: 1.55).

conclusionIn Asian patients with early cervical cancer, DM is an independent unfavorable prognostic factor influencing both OS and CSS, even after curative treatments. IMPLICATIONS FOR PRACTICE: Type 2 diabetes mellitus (DM) increases the incidence of several types of cancer but not cervical cancer (CC); however, less is known about the impact of DM on patients who already have CC. This study suggests that DM may increase the risk of cancer recurrence and death for early stage CC patients, even after curative treatments. Incorporating DM control should be considered part of the continuum of care for early stage CC patients, and close surveillance during routine follow-up in this population is recommended.

Indexed as

AdultAgedAged, 80 and overDiabetes Mellitus, Type 2Early Detection of CancerFemaleHumansMaleMiddle AgedPrognosisProportional Hazards ModelsRegistriesRisk FactorsSurvival AnalysisTaiwanUterine Cervical NeoplasmsCancer registryCancer-specific survivalCervical cancerDiabetes mellitusPrognosis

Identifiers

PMID26240133
PMCPMC4571799
OpenAlexW2224022416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.